- Home
- SRRK
as 06-20-2025 4:00pm EST
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 3.2B | IPO Year: | 2018 |
| Target Price: | $42.17 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.76 - $46.98 | Next Earning Date: | 08-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 502.60% |
Stock Insider Trading Activity of Scholar Rock Holding Corporation (SRRK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Parlavecchio Caryn | SRRK | CHRO | Jun 16 '25 | Sell | $32.00 | 6,186 | $197,960.66 | 157,642 | |
| Ho Junlin | SRRK | GENERAL COUNSEL | Jun 16 '25 | Sell | $32.00 | 7,442 | $238,154.42 | 222,569 | |
| Peng Katie | SRRK | Director | Jun 16 '25 | Sell | $32.24 | 3,031 | $96,888.38 | 34,974 | |
| Burow Kristina | SRRK | Director | May 29 '25 | Sell | $29.54 | 5,400 | $160,510.62 | 25,471 | |
| Reed Joshua | SRRK | Director | May 29 '25 | Sell | $29.86 | 5,400 | $160,462.57 | 16,232 | |
| Brudnick Richard | SRRK | Director | May 29 '25 | Sell | $29.82 | 6,075 | $180,530.67 | 16,457 | |
| Vaishnaw Akshay | SRRK | President of R&D | May 29 '25 | Sell | $29.82 | 6,750 | $200,612.03 | 617,825 | |
| Gilman Michael | SRRK | Director | May 29 '25 | Sell | $29.53 | 3,375 | $100,304.05 | 55,216 | |
| Sacco Tracey | SRRK | Chief Commercial Officer | Apr 25 '25 | Sell | $33.15 | 5,000 | $164,130.79 | 71,834 | |
| Sacco Tracey | SRRK | Chief Commercial Officer | Mar 24 '25 | Sell | $33.30 | 6,500 | $215,014.05 | 71,834 |
Latest Scholar Rock Holding Corporation News
SRRK Breaking Stock News: Dive into SRRK Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial
Motley Fool
3 days ago
Why Scholar Rock Shares Are Soaring Today
Investopedia
3 days ago
Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results
MT Newswires
3 days ago
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
MT Newswires
3 days ago
Traders Eye Fed Decision, Driving Muted Premarket Action for US Equity Futures
MT Newswires
3 days ago
Sector Update: Health Care
MT Newswires
3 days ago
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Announcement Amid Geopolitical Tensions
MT Newswires
3 days ago
Scholar Rock Says Apitegromab With Tirzepatide Improves Weight Loss Quality in Phase 2 Trial
Compare SRRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRRK Scholar Rock Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.